- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Elbit selects restructuring adviser
Israel-based Elbit has chosen Salomon Brothers of New York Cityas its financial adviser and investment banker to help plan aproposed corporate reorganization. Salomon Brothers will help Elbit managers examine the feasibilityof realigning Elbit and its
Israel-based Elbit has chosen Salomon Brothers of New York Cityas its financial adviser and investment banker to help plan aproposed corporate reorganization.
Salomon Brothers will help Elbit managers examine the feasibilityof realigning Elbit and its subsidiaries into new and independenthealthcare, defense and commercial companies. Elbit's board ofdirectors approved this examination in principle on Dec. 7 (SCAN12/27/95).
The selection of Salomon Brothers as financial adviser is oneof two interim steps toward a final reorganization plan, accordingto Dr. Thomas Spackman, president of Elscint's U.S. subsidiary.The selection of a management consultant to help guide planningis still pending, he said.
In other Elscint news, the company's shareholders have approvedthe sale of Elscint's Elscintec ultrasound subsidiary to Elbit.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
